哮喘维持治疗中ICS/LABA联合吸入激素剂量反应关系的系统综述与Meta分析
高剂量对比中剂量ICS/LABA可降低重度急性发作风险(Peto OR 0.81,95%CI 0.67-0.98),高证据等级,其他疗效与安全性无重要差异。高低剂量及中低剂量对比各结局无差异。
要点
- 高剂量对比中剂量ICS/LABA降低重度急性发作风险(Peto OR 0.81)。
- 高剂量与中剂量ICS/LABA在其他疗效和安全性结局上无临床重要差异。
- 高剂量ICS/LABA绝对获益取决于患者重度急性发作风险,高风险者可能更有意义。
核心结论
- 维持高剂量ICS/LABA相比中剂量可降低约20%重度急性发作的比值,高证据等级。
主要发现
- 高剂量对比中剂量ICS/LABA降低重度哮喘急性发作风险(Peto OR 0.81,95%CI 0.67-0.98),高证据等级。
- 高剂量与中剂量ICS/LABA在其他疗效和安全性结局上无临床重要差异。
- 高剂量对比低剂量、中剂量对比低剂量ICS/LABA在所有结局上均无差异。
关键数值与推荐
- 高剂量对比中剂量ICS/LABA的重度急性发作Peto OR为0.81(95%CI 0.67-0.98)。
临床怎么用
- 对重度急性发作高风险哮喘患者,可考虑高剂量ICS/LABA以降低发作风险。
- 高剂量与中剂量ICS/LABA在其他结局上无重要差异,需权衡风险与获益。
局限性
- 高剂量对比低剂量及中剂量对比低剂量的研究数量有限,限制结论可靠性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: High doses of a maintenance inhaled corticosteroids (ICSs) in asthma may achieve only modest additional clinical benefit beyond low-to-medium doses and are associated with an increased risk of adverse systemic effects. The ICS dose-response relationship when administered as maintenance combination ICS/long-acting beta2-agonist (LABA) therapy is uncertain. RESEARCH QUESTION: What is the ICS dose-response of maintenance ICS/LABA therapy? STUDY DESIGN AND METHODS: A systematic review was conducted using MEDLINE, Embase, the Cochrane Register of Controlled Trials, and ClinicalTrials.gov databases to identify randomized controlled trials that allocated participants to > 1 ICS dose category, per Global Initiative for Asthma categorization, administered in combination with ICS/LABA inhalers. Meta-analysis compared outcomes of high-dose (HD) and medium-dose (MD), HD and low-dose (LD), and MD and LD ICS/LABA. The primary outcome was the proportion of participants with ≥ 1 severe asthma exacerbation; secondary outcomes were patient-reported outcome measures of asthma control, spirometry, and serious adverse events. Certainty of evidence was assessed by using the Grading of Recommendations, Assessment, Development and Evaluations domains. RESULTS: Twelve randomized controlled trials (6,373 participants) were identified: 7 comparing HD vs MD ICS/LABA, 1 HD vs LD ICS/LABA, and 4 MD vs LD ICS/LABA. HD vs MD ICS/LABA reduced the odds of a severe asthma exacerbation (Peto's OR, 0.81; 95% CI, 0.67-0.98) with high certainty. There were no other clinically important differences in efficacy or safety outcomes of HD vs MD ICS/LABA. There was no difference in all outcomes comparing HD with LD or MD with LD ICS/LABA. INTERPRETATION: Our results showed that maintenance HD ICS/LABA reduced the odds of a severe exacerbation by about 20% compared with MD ICS/LABA. The absolute reduction in severe exacerbation risk with HD ICS/LABA is determined by patients' exacerbation risk, and this effect size may be clinically relevant for patients if this risk is high. Comparisons of other doses of ICS/LABA were limited by the number of identified studies, although no large difference in effect sizes were observed.
引用
- Noble, Warhurst, Cullen, et al. The Dose-Response of Inhaled Corticosteroids in Combination Inhaled Corticosteroid/Long Acting Beta2-Agonist Maintenance Therapy for Asthma: A Systematic Review and Meta-Analysis. Chest. 2025. PMID: 40912294. doi:10.1016/j.chest.2025.08.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。